跳至主要内容
临床试验/EUCTR2017-003509-16-IT
EUCTR2017-003509-16-IT进行中(未招募)1 期

Serum cytokine levels as predictors of the efficacy of aflibercept in combination with FOLFIRI in metastatic Colo-Rectal Cancer patients (mCRC) - FLIBER

FONDAZIONE RICERCA TRASLAZIONALE (FORT)0 个研究点目标入组 124 人开始时间: 2022年1月20日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
124

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Adult age (>= 18 years old);
  • 2. An Eastern Cooperative Oncology Group (ECOG);
  • performance status (PS) of 0 or 1;
  • 3. Histologically or cytologically proven colorectal
  • adenocarcinoma with metastatic disease not menable to potentially curative treatment;
  • 4. Measurable disease according to the RECIST criteria 1.1;
  • 5. Documented progression while on or after completion of a single prior oxaliplatin-containing regimen in patients treated in the neoadjuvant and metastatic setting; documented relapsing disease within 6 months of completion of oxaliplatinbased regimen in patients treated in the adjuvant setting;
  • 6. Aflibercept in combination with irinotecan planned as per standard clinical practice and decision by the treating oncologist;
  • 7. Any adverse events from prior anticancer therapy must have recovered to grade = 1 ([NCI-CTCAE] version 5.0) before study enrolment;
  • 8. Patients were to have adequate bone marrow, liver and renal: alanine transaminase (ALT) = 3 × institutional upper limit of normal (ULN) [= 5 × ULN in presence of liver metastases], total bilirubin = 1.5 × institutional ULN [= 2.0 x ULN in presence of liver metastases], neutrophil count = 1.5 x 109/L, platelet count = 100 x 109/L, proteinuria ¿ 1+ on the dipstick, creatinine = 2.5 x institutional ULN or creatinine clearance of =40 mL/min;
  • 9. Signed written consent form;
  • 10. Patients of reproductive potential, must use adequate contraception methods;
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 62
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 62

排除标准

  • 1. Radiation therapy or any previous anti-neoplastic systemic treatment within the past 28 days before study enrollment;
  • 2. History of major surgery within 28 days before study enrollment; 3. Known prior malignancies or known brain metastases ( patients with adequately treated basal cell or squamous cell skin cancer,
  • carcinoma in situ of the cervix, or any other cancer from which the patient had been disease-free for more than 10 years are permitted);
  • 4. Severe acute or chronic medical condition that may impair the ability to participate in the study or may interfere with the interpretation of results;
  • 5. Any contraindication to the administration of aflibercept, irinotecan, 5-fluorouracil or folinic acid;
  • 6. History of any auto-immune or rheumatic disease; any active bacterial or viral infection;
  • 7. History of uncontrolled hypertension and diabetes within 3 months before enrollment;
  • 8. History of daily use of corticosteroids or immune-suppressive medications;
  • 9. Deep vein thrombosis within 4 weeks before treatment;
  • 10. Pregnant and breast-feeding women;
  • 11. Patients of reproductive potential who refuse to use effective methods of contraception;

研究者

发起方
FONDAZIONE RICERCA TRASLAZIONALE (FORT)

相似试验